Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022  by Bioinformatics  and Cancer Database Analysis

Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022 by Bioinformatics and Cancer Database Analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022 by Bioinformatics and Cancer Database Analysis Wei Xu, Yifan Wu, Hao Lu, Wanlin Xu, Shengwen Liu, Wenjun Yang This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4705733/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objectives: Oral squamous cell carcinoma (OSCC) is a prevalent malignant tumor worldwide, posing a significant threat to patient survival. Induction chemotherapy (IC) is an established therapeutic approach for advanced, unresectable OSCC, proven effective in controlling tumor progression and preventing distant metastasis. Despite its clinical significance, there is a lack of bibliometric studies in this research domain. This article aims to address this gap by conducting a comprehensive bibliometric analysis, which will shed light on the key areas of focus and provide insights into the research landscape of OSCC induction chemotherapy. Methods: The relevant articles were identified using the Web of Science Core Collection (WoSCC). To examine the co-occurrence relationships across countries/regions, institutes, authors (cited authors), journals (cited journals), references, and keywords in this research field, bibliometric analysis was conducted with the assistance of two software tools, VOSviewer and CiteSpace. This approach enables a comprehensive exploration of the frontiers and hotspots within the field. Results: A comprehensive collection of 227 publications was assembled between 2000 and 2022. Overall, both the number of publications and citations display a steady annual increase, with the peak observed in 2021 and 2022. China and the United States jointly occupy the first rank in terms of total publications (n = 46), with Japan following closely behind (n = 32). Among the academic institutions, Shanghai Jiao Tong University has made the most substantial contribution, with 26 publications. In the realm of authors, Zhong Laiping secures the top position in the list of the top 10 authors (n = 13), whereas Posner MR and Vermorken JB are equally distinguished as the most co-cited authors (n = 104). The research field's most prolific journal is Oral Oncology, which boasts the highest number of publications (n = 24), while the Journal of Clinical Oncology claims the greatest number of co-citations. Conducting a co-occurrence and cluster analysis on the references cited, it was discovered that the recent research focus has shifted from radiochemotherapy and oral cancer to paclitaxel. Keyword analysis unveils that current research on induction chemotherapy for OSCC underscores the significance of chemotherapeutic drugs such as cisplatin, docetaxel, and fluorouracil. Conclusion: Despite the relatively modest number of publications, research on induction chemotherapy for OSCC is steadily growing. Currently, the primary focus of investigation revolves around drug selection for this therapeutic approach. This article provides an overview of the prevailing trends in this field and identifies potential directions and hotspots for future research. Oral squamous cell carcinoma induction chemotherapy bibliometric study VOSviewer CiteSpace Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 1. Introduction Oral squamous cell carcinoma (OSCC) is a prevalent cancer type that affects the oral cavity, leading to a high mortality rate and imposing a significant healthcare burden globally [ 1 ] . Current treatment options for OSCC, including surgery, radiotherapy, and chemotherapy, have limited efficacy, particularly in advanced stages of the disease. Furthermore, these treatments often result in severe side effects and a diminished quality of life for patients [ 2 ] . In recent years, there has been growing interest in the development of targeted therapies for OSCC, such as induction chemotherapy. Induction chemotherapy involves administering drugs prior to the primary treatment to shrink the tumor and enhance its response to subsequent therapy [ 3 ] . This approach aims to increase the chances of a successful outcome and improve the overall survival rate of OSCC patients. Preclinical and clinical studies have shown promising results with the use of induction chemotherapy in OSCC [ 4 ] . Various chemotherapeutic agents, including cisplatin, docetaxel, and 5-fluorouracil, have been used alone or in combination to induce tumor regression [ 5 , 6 ] . The success of induction chemotherapy lies in its ability to enhance the sensitivity of OSCC cells to radiation or surgery, thereby increasing the effectiveness of subsequent treatments [ 7 ] . However, despite its potential benefits, there are several challenges that need to be addressed, such as chemotherapy drug resistance, toxic side effects, and the absence of reliable biomarkers for patient selection and treatment response monitoring [ 8 ] . Additionally, optimizing the timing, dosage, and duration of induction chemotherapy is crucial to maximize its therapeutic benefits [ 9 ] . Bibliometric studies play a crucial role in evaluating the scientific output and impact of research in various fields [ 10 – 12 ] . Recently, there has been a significant increase in publications related to induction chemotherapy in OSCC, emphasizing the importance of identifying key contributors, institutions, and countries involved in this research area. However, there has been a lack of specific bibliometric studies focusing on the knowledge graph of induction chemotherapy in OSCC. This study aims to conduct a comprehensive bibliometric analysis of the literature from 2000 to 2022, examining induction chemotherapy in OSCC. The findings will contribute to a better understanding of the research landscape and guide future research endeavors in this field. 2. Materials and methods Data sources and search strategies A systematic approach was employed to conduct a comprehensive bibliometric study on induction chemotherapy (IC) in oral squamous cell carcinoma (OSCC) and identify relevant publications. The Web of Science Core Collection (WoSCC) database was searched using a carefully designed search strategy. Two search lists were used, combining relevant keywords with the 'and' operator. The first list covered terms related to oral squamous cell carcinoma, including 'oral squamous cell carcinoma,' 'oral cancer,' and 'OSCC.' The second list included terms associated with induction chemotherapy, such as 'induction chemotherapy' and 'neoadjuvant chemotherapy.' The search was limited to English-written articles published between January 1, 2000, and December 31, 2022. Inclusion criteria were established for article selection, which consisted of studies focusing on induction chemotherapy in oral squamous cell carcinoma, original research or literature reviews, and availability of full-text articles. Two authors (Xu Wand Wu YF) independently conducted the search in the WoSCC database, downloading the relevant literature in TXT format, which included titles, keywords, author information, abstracts, references, etc. Any discrepancies encountered during the search process were resolved through discussion or consultation with third-party experts (Liu SW and Yang WJ). Bibliometrics analysis and visualization Following the initial search and screening process, the selected articles underwent meticulous examination to extract significant bibliometric data. The extracted data encompassed publication year, author names, affiliations, journal titles, citation counts, and collaboration networks. Microsoft Excel 2019 was employed to generate comprehensive reports on annual publications and citations. For the purposes of bibliometric and visual analysis, CiteSpace (6.2.R4) and VOSviewer (1.6.19) were utilized. These tools facilitated the identification of countries, institutions, authors, journals, references, and keywords, as well as the exploration of network characteristics and keyword bursts. VOSviewer was particularly useful in investigating collaborative networks among organizations, countries, journals, co-cited journals, authors, co-cited authors, co-cited references, and keywords. The size of nodes in the collaborative networks denoted their frequency of occurrence or reference. CiteSpace was employed to detect keyword and reference bursts, utilizing specific parameters such as a time span of 2000–2022 (slice length = 1), selection criteria of g-index (k = 5), link retaining factor (LRF = 3), look back years (LBY = 5), and e for top N (e = 1). Additionally, links were determined based on cosine strength within slices, and a minimum duration of 1 was established. Consequently, a timeline view of co-cited references was generated, along with a dual-map overlay highlighting the interrelations between journals in the induction chemotherapy of OSCC. 3. Results Global growth trend in publication outputs and citations A search of the Web of Science (WOS) database identified a total of 227 articles published between 2000 and 2022 on induction chemotherapy for oral squamous cell carcinoma. As depicted in Fig. 1 , there was a significant fluctuation in the number of published articles, with an overall upward trend. Prior to 2012, the annual article count remained below 10, reaching a low of just one article in 2007. However, after 2013, the annual article count exceeded 10, peaking in 2014 with 19 articles, before gradually declining to around 12 articles per year. Following 2020, there was a gradual increase in the number of articles, resulting in a tie for the highest number of articles in 2021 and 2022, with 21 articles each. Overall, the total number of research papers in this field remains relatively low. However, it is noteworthy that the citation rate of articles related to induction chemotherapy for oral squamous cell carcinoma has consistently increased over time, indicating a growing interest among international scholars in this research area. Distribution of countries/regions and institutions A total of 227 articles were collected from 28 different countries or regions. Table 1 displays the top ten countries with the highest number of articles. China and the United States rank first (n = 46, 20.26%), followed by Japan (n = 32, 14.10%). However, when considering citations, the United States takes the lead (n = 3387), followed by France (n = 2090) and China (n = 727). Figure 2 illustrates the close and extensive collaborations between countries, especially between the US and China. Table 1 Top 10 countries/regions publishing research articles on induction chemotherapy for OSCC Rank Country/Regions Publications Citations 1 China 46 727 2 USA 46 3387 3 Japan 32 289 4 India 28 263 5 Germany 26 624 6 Taiwan 15 174 7 Italy 11 295 8 France 8 2090 9 Brazil 6 116 10 Hungary 6 63 These articles originated from 372 institutions, including Shanghai Jiao Tong University (n = 26, 11.45%) in China, The University of Texas MD Anderson Cancer Center (n = 13, 5.73%) in the United States, and Tata Memorial Hospital (n = 11) in India, all of which have contributed more than 10 publications, as shown in Table 2 . Figure 3 exhibits the inter-institutional collaborations, highlighting the close partnerships between Shanghai Jiao Tong University and various domestic and international institutions, such as The University of Texas MD Anderson Cancer Center and the Shanghai Key Laboratory of Stomatology. Table 2 Top 5 institutions publishing research articles on induction chemotherapy for OSCC Rank Institution Publications Citations 1 Shanghai JiaoTong University 26 575 2 The University of Texas MD Anderson Cancer Center 13 416 3 Tata Memorial Hospital 11 180 4 University of Cologne 6 130 5 Malabar Cancer Centre 5 20 5 Shanghai Key Laboratory of Stomatology 5 15 Analysis of authors and co-cited authors A total of 1609 authors participated in studies concerning induction chemotherapy for oral squamous cell carcinoma. Among them, four authors from China, namely Zhong Laiping (n = 13), Zhang Zhiyuan (n = 12), Zhang Chenping (n = 11), and Li Jiang (n = 10), had more than 10 individual publications (Table 3 ). Furthermore, as depicted in Fig. 4 A, the nodes in the graph represent the number of publications, with Zhong Laiping and Zhang Chenping having the largest node. This suggests that these two authors were in communication and collaboration with other authors including Zhu Dongwang, Zhao Tongchao, Ju Wutong, Guo Wei, Ren Guoxin. Table 3 Top 10 authors and co-cited authors involved in OSCC induction chemotherapy research Rank Author Counts Citations Rank Co-cited Author Citations 1 Zhong Laiping 13 412 1 Posner MR 104 2 Zhang Zhiyuan 12 363 2 Vermorken JB 104 3 Zhang Chenping 11 359 3 Zhong LP 89 4 Li Jiang 10 308 4 Pignon JP 86 5 Wang Lizhen 9 308 5 Licitra L 75 6 Liu Ying 8 184 6 Hitt R 63 7 Guo Wei 7 255 7 Forastiere AA 59 7 Ren Guoxin 7 33 8 Cohen EEW 57 7 Zhu Dongwang 7 79 8 Vokes EE 57 10 Kovács ÁF 6 121 10 Bernier J 56 10 Vanita Noronha 6 29 10 Haddad RI 56 10 Vijay Maruti Patil 6 153 10 Kumar Prabhash 6 27 Among the 3885 co-cited authors, Vermorken JB and Posner MR tied for first place with a frequency of 104 citations. They are followed by Zhong Laiping (n = 89) and Pignon JP (n = 86) (Table 3 ). Lastly, we identified the top 40 authors with over 20 citations and constructed a network of co-cited authors (Fig. 4 B). Analysis of journals and co-cited journals According to the data presented, a total of 111 journals have published literature related to induction chemotherapy for oral squamous cell carcinoma. The journal with the highest number of publications on this topic is Oral Oncology, with 24 articles. It is closely followed by Head and Neck - Journal for the Sciences and Specialties of the Head and Neck, which has published 11 articles, and Indian Journal of Cancer with 8 articles (Table 4 ). When considering the impact factor of the journals, the top three journals with the highest impact factors are Annals of Oncology from the Netherlands (IF = 50.5) with six publications, Journal of Clinical Oncology (IF = 45.3) with 4 publications, and Cancer (IF = 6.2) from the USA with five publications. The majority of the top ten journals with the highest impact factors are American journals, accounting for 42.86% of the total journals and taking the first place in the list. Creating a journal network by filtering out the journals with more than four publications, it was observed that Oral Oncology had active citation with Journal of Clinical Oncology, Annals of Oncology, and Head and Neck - Journal for the Sciences and Specialties of the Head and Neck (Fig. 5 A). Table 4 Top 10 journals by several publications and co-citations Rank Journal Publications Country IF (2022) Rank Co-cited Journal Citation Country IF (2022) 1 Oral Oncology 24 England 4.8 1 Journal of Clinical Oncology 906 USA 45.3 2 Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 11 USA 2.8 2 New England Journal of Medicine 415 USA 158.4 3 Indian Journal of Cancer 8 India 1.0 3 International Journal of Radiation Oncology Biology Physics 363 USA 6.9 4 Annals of Oncology 6 Netherland 50.5 4 Oral Oncology 362 England 4.8 5 Anticancer Research 5 Greece 1.9 5 Annals of Oncology 263 Netherland 50.5 6 BMC Cancer 5 England 3.8 6 Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 261 USA 2.8 7 Cancer 5 USA 6.2 7 Cancer 213 USA 6.2 8 Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology 5 USA NA 8 Radiotherapy and Oncology 189 Netherland 5.6 9 Cancer Chemotherapy and Pharmacology 4 USA 2.9 9 Lancet Oncology 133 England 51.1 10 Journal of Clinical Oncology 4 USA 45.3 10 British Journal of Cancer 127 England 8.8 11 Journal of Oral Pathology & Medicine 4 Denmark 3.3 12 Oncology Letters 4 Greece 2.8 13 Oncotarget 4 USA NA Table 4 provides information on co-cited journals, showing that there are four journals with more than 300 citations. Journal of Clinical Oncology ranks first with 906 citations, followed by New England Journal of Medicine (415 citations), International Journal of Radiation Oncology Biology Physics (363 citations), and Oral Oncology (362 citations). These highly cited journals have different impact factors, with New England Journal of Medicine ranking highest (IF = 158.4). Figure 5 B illustrates the journal network constructed with several co-cited journals meeting a minimum 30 of citations criteria. It portrays the co-citation relationship among journals, and the most cited journals in this network are Journal of Clinical Oncology, Annals of Oncology, Cancer, and International Journal of Radiation Oncology Biology Physics. These journals have a strong relationship in terms of citations. The dual map overlay of journals illustrates the citation relationships between the citing journals (on the left) and the co-cited journals (on the right) (Fig. 6 ). The primary citation paths are represented by yellow and two green paths. These paths indicate that studies published in Molecular/Biology/Genetics journals were predominantly cited by articles in Molecular/Biology/Immunology and Medicine/Medical/Clinical journals. On the other hand, studies published in Health/Nursing/Medical journals were predominantly cited by literature in Medicine/Medical/Clinical journals (Fig. 6 ). Analysis of co-cited references and reference with citation burst From 2000 to 2022, a total of 5250 co-cited references were identified in the research on induction chemotherapy for oral squamous cell carcinoma. Eight out of the top ten most highly cited articles exceeded 30 citations (Table 5 ). The article with the highest number of citations was "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer" by Vermorken JB, published in the New England Journal of Medicine (IF = 158.5) in 2007. Pignon JP had two articles in the top ten, published in Lancet (IF = 168.9) in 2000 and in Radiotherapy and Oncology (IF = 5.7) in 2009. A co-citation network was constructed using 21 articles with more than 20 citations (Fig. 7 A). Vermorken JB's 2007 article in the New England Journal of Medicine had strong co-citation relationships with Vermorken JB's 2007 article in the same journal and Haddad R's 2013 article in Lancet Oncology. Additionally, a timeline displaying the co-cited references was generated (Fig. 7 B). The timeline view is a data visualization method that combines clustering and time slicing techniques. The clustering labels are sorted based on their appearance order. The main terms of the co-cited references ranged from "#5 radiochemotherapy" in 2000 to "#0 paclitaxel" from 2015 to 2021. Table 5 Top 10 co-cited references on research of induction chemotherapy for OSCC Rank Title Journal First author Year Citations #1 Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer New England journal of medicine Jan B Vermorken 2007 81 #2 Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer New England journal of medicine Marshall R Posner 2007 79 #3 Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial Journal of Clinical Oncology Lisa Licitra 2003 61 #4 Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma Journal of Clinical Oncology Lai-ping Zhong 2013 55 #5 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial Lancet Oncology Robert Haddad 2013 47 #6 Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer Lancet J P Pignon 2000 43 #7 Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiotherapy and Oncology J P Pignon 2009 40 #8 Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer Journal of Clinical Oncology Ezra E W Cohen 2014 38 #9 Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo JNCI-Journal of the National Cancer Institute A Paccagnella 1994 29 #10 Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer New England Journal of Medicine Jacques Bernier 2004 28 #10 Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group JNCI-Journal of the National Cancer Institute J L Lefebvre 1996 28 10 Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer New England Journal of Medicine Gregory T Wolf 1991 28 Figure 8 presents the highly cited references, which are those frequently cited by scholars in the field over a certain period. We utilized CiteSpace software to analyze the top ten strong citation bursts, where the red bars represent the periods of intense citation activity. The earliest citation burst occurred in 2002, and the latest burst was observed in 2022. The article with the strongest burst was "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer," which spanned from 2015 to 2019. It was followed by the article "Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma" from 2013 to 2018, and "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial" from 2014 to 2018. Overall, the burst intensities of these articles ranged from 5.16 to 8.76, and the durations of the bursts varied from 2 to 5 years. Analysis of keywords A density visualization of keywords was constructed using VOSviewer (Fig. 9 A). The yellow portion represents keywords with high frequency, while CiteSpace (Fig. 9 B) was utilized to identify the top ten keywords with the strongest citation bursts. Figure 9 B displays the period from 2000 to 2022 using the blue line, while the red line depicts the period associated with each burst keyword. The earliest burst keyword, "head and neck cancer," emerged in 2003 with a strength of 3. 79. In recent years, the prominent keywords are primarily "phase III trial" (strength = 4.36, 2014–2020), "surgery" (strength = 3.47, 2018–2022), and "concurrent chemoradiotherapy" (strength = 2.3, 2019–2022). 4. Discussion General Information We conducted a systematic review of articles published between 2000 and 2022 that focused on induction chemotherapy for oral squamous cell carcinoma. After excluding studies that did not meet the predefined screening criteria, our analysis comprised 227 English-language articles from 111 journals and 5,250 co-cited references originating from 372 institutions across 28 countries/regions. Our findings indicate a gradual, albeit fluctuating, increase in research on induction chemotherapy for oral squamous cell carcinoma since 2000, although the overall publication output remains relatively low. Notably, three significant shifts emerged in 2008, 2013, and 2020. These turning points were characterized by substantial increases in publication volume compared to the preceding year. This can be attributed to the exploration of the efficacy and safety of various chemotherapy drugs, such as cisplatin and 5-fluorouracil, in multiple studies in 2008, along with corresponding phase I and II clinical trials [13-16] . In 2013, the phase III clinical trial of TPF regimen for oral squamous cell carcinoma by Zhong Laiping further advanced research in this field [17, 18] . In 2020, molecular biology and immunotherapy contributed to the development of personalized chemotherapy based on molecular targets and combination immunotherapy, bringing oral squamous cell carcinoma treatment back into the public [19-24] . China and the United States shared the top spot in terms of publication count. Notably, three of the top four countries are from Asia (China, India, and Japan), reflecting the high incidence of oral cancer in the region. The distribution of institutions matches the distribution of countries/regions. The top three institutions are from China, USA, and India. Close collaboration between countries/regions and institutions was observed, particularly between China and the United States, as well as multi-party collaborations centered around China and the United States. Among the top ten active authors in terms of publication volume, each author has published at least five articles, and the top four authors have published more than ten articles, with citation counts of more than 300 for all articles. Among these thirteen prolific authors, twelve from Asia, comprising nine Chinese scientists affiliated with Shanghai Jiao Tong University and three researchers from India's Tata Memorial Hospital. This finding suggests that Asian researchers have played an important role and made significant contributions to the research on induction chemotherapy for oral squamous cell carcinoma. Co-cited authors assume a pivotal role in this field. Among the top ten co-cited authors, only Posner MR and Vermorken JB have been co-cited more than 100 times (co-citations = 104). Zhong Laiping, who ranks first in terms of publication volume, ranks third with 89 co-citations. These three authors have conducted clinical trials on PF and TPF induction chemotherapy for oral squamous cell carcinoma. In addition, Posner MR and Vermorken JB further investigated the efficacy of induction chemotherapy regimens in combination with cetuximab, while Zhong Laiping conducted a pilot study on the neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib in 2022, opening new avenues for research in induction chemotherapy for oral squamous cell carcinoma [5, 6, 16, 17, 25] . The top ten journals accounted for only 94 papers, representing 41% of the total publications in this research domain. Oral Oncology claimed the top position with 24 publications, followed by Head and Neck-Journal for the Sciences and Specialties of the Head and Neck with 11 publications and Indian Journal of Cancer with eight publications. This indicates that these journals are particularly interested in articles related to induction chemotherapy research of oral squamous cell carcinoma. This data will help future scientists in selecting journals for submitting manuscripts in terms of this field. Furthermore, following a thorough analysis of authorship, co-cited authors, and co-cited references, we identified Zhong Laiping as the sole researcher present in all three categories. This suggests that he is an accomplished author in the field, and his team is an excellent research team. His team has the potential to be excellent collaborators for researchers. Knowledge base When two publications are co-cited by a third publication, it establishes a co-citation relationship. The significance of a document in a specific field increases as it receives more citations. This reflects the knowledge base and primary concerns of researchers in that field [26] . Table 5 presents the top ten most cited articles, comprising 11 publications that originate from renowned international journals with high impact factors. Among these, nine articles are clinical trials, while the remaining two are meta-analyses. These clinical trials primarily investigate the selection of induction chemotherapy regimens for advanced oral squamous cell carcinoma and conduct phase II or III clinical trials to assess the effectiveness of induction chemotherapy. The first clinical trial conducted in 1994 showed that neoadjuvant chemotherapy reduced the incidence of distant metastases in operable patients and improved local control, distant metastasis incidence, complete remission, and overall survival in inoperable patients [27] (#9). The most cited article, a phase III clinical trial by Jan B Vermorken in 2007 [6] (#1), compared the efficacy of two induction chemotherapy regimens (TPF and PF) in locally advanced, unresectable oral squamous cell carcinoma. It found that the TPF regimen significantly improved progression-free survival and overall survival compared to the PF regimen. In the same year, Marshall R Posner conducted a phase III clinical trial [5] (#2) that also concluded that the TPF induction chemotherapy regimen in combination with radiotherapy was more effective than the PF regimen. However, a study by Robert Haddad in 2013 [7] (#5) compared the efficacy of concurrent chemoradiotherapy after induction chemotherapy with TPF versus concurrent cisplatin-based chemoradiotherapy alone in patients with locally advanced unresectable head and neck cancer. It found that preoperative induction chemotherapy with TPF did not significantly improve patient survival. Another study by Zhong Laiping [4] (#4) suggested that in patients with respectable stage III or IV oral squamous cell carcinoma, TPF-induced chemotherapy was not effective in improving survival compared to surgery. Similarly, Lisa Licitra's study [28] (#3) found that adding TPF chemotherapy to standard surgery did not improve survival. A subsequent study by Ezra E W Cohen [29] (#8) concluded that induction chemotherapy did not significantly improve overall survival in patients with advanced N2, N3 head and neck squamous cell carcinoma compared to chemoradiotherapy alone. Based on these co-citation relationships, it can be inferred that the efficacy of induction chemotherapy regimens for advanced oral squamous cell carcinoma is a topic of interest and discussion among researchers in the field. Two meta-analyses investigating the effectiveness of chemotherapy in the treatment of head and neck squamous cell carcinoma indicated that concurrent chemotherapy was more beneficial for patients compared to induction chemotherapy [30] (#7). However, a previous study published in The Lancet presented opposing findings, suggesting that chemotherapy had limited impact on patient survival [31] (#6). Overall, these ten highly cited papers provide a comprehensive evaluation and analysis of the efficacy of induction chemotherapy for advanced oral squamous cell carcinoma. Additionally, they delve into the exploration and enhancement of induction chemotherapy regimens. Furthermore, the application of co-citation analysis furnishes us with valuable insights into the evolution of the knowledge structure pertaining to induction chemotherapy for oral squamous cell carcinoma. Research frontiers To explore and identify new areas of research in induction chemotherapy for oral squamous cell carcinoma, we utilized CiteSpace to analyze co-cited references. Figure 7B demonstrates that earlier studies conducted between 2000 and 2005 mainly focused on investigating the effectiveness of sequential treatment involving chemotherapy combined with radiotherapy for OSCC, specifically referred to as "#5 radiochemotherapy". Notably, preoperative concurrent chemoradiotherapy followed by radical surgery has yielded promising long-term outcomes for advanced squamous cell carcinoma of the oral cavity. Studies conducted by Kirita et al. showcased high response rates both clinically and pathologically, along with impressive survival rates at 5 and 10 years [32, 33] . This treatment regimen also resulted in notable clinical tumor response rates, acceptable acute toxicity, and minimal late therapeutic complications [33] . Individuals who achieved favorable histopathological responses exhibited superior survival rates when compared to those with substantial residual tumors [34] . Furthermore, Klug et al.'s study discovered that preoperative radiochemotherapy combined with radical surgery led to a 5-year overall survival probability of 53.9%, along with a 5-year local control probability of 70.2% [35] . Similarly, Eich et al. reported positive outcomes with neoadjuvant radiochemotherapy followed by radical surgery, demonstrating an overall survival of 65% at 2 years and 45% at 5 years [36] . These findings strongly indicate that preoperative concurrent chemoradiotherapy followed by radical surgery serves as an effective and safe treatment option for advanced oral cavity squamous cell carcinoma. Currently, the primary attention is directed towards the selection of induction chemotherapy regimens for OSCC. Additionally, new approaches involving the combination of induction chemotherapy and immunotherapy, such as "#0 paclitaxel", are under investigation. Paclitaxel (PTX), a member of the taxane family, has shown broad antitumor activity and is commonly used in the treatment of various solid tumors, including OSCC. Its primary mode of action is by disrupting microtubule dynamics, leading to mitotic arrest and eventual cell death [37] . Another taxane chemotherapeutic agent, docetaxel, is commonly used for induction chemotherapy in OSCC as a TPF regimen, which includes 5-fluorouracil and cisplatin, since it is a microtubule inhibitor like PTX. Data from randomized trials suggest that TPF sequential therapy may be a viable alternative to concurrent chemoradiotherapy in certain patients. TPF therapy is generally well-tolerated, but does have a higher incidence of hematologic adverse events, including neutropenia and complications linked with neutropenia, compared to PF therapy [38] . PTX has demonstrated broad antitumor activity as a stand-alone treatment or in combination with other chemotherapy agents. For instance, several scholars have conducted clinical studies in recent years, concentrating on the effectiveness of combining cetuximab with traditional TPF chemotherapy in advanced OSCC [39, 40] . Additionally, some basic experiments have confirmed that the combination of PTX and cetuximab boosts the antitumor activity of OSCC through inhibition of the NF-κB activity [41] . Yuta Sawatani et al. discovered that PTX increased the anti-cancer impact of cetuximab in vitro by improving antibody-dependent cytotoxicity (ADCC) in OSCC cells [42] . Tumor immunotherapy generates immune responses against tumors by enhancing the body's immune system. Recently, progress has been made in understanding the potential application of classical drugs in tumor immunotherapy. Numerous studies have shown that paclitaxel can directly kill tumor cells and modulate various immune cells, such as effector T cells, dendritic cells (DCs), natural killer cells (NK cells), regulatory T cells (Tregs), and macrophages [43] . Paclitaxel can inhibit the function of Tregs and reverse tumor immune escape. Therefore, the combination of paclitaxel and immunotherapy can enhance treatment efficacy [43] . Recent research has focused on combining paclitaxel with immunotherapies to improve treatment outcomes. The combination therapy of paclitaxel and immune checkpoint inhibitors has shown promising efficacy signals in clinical trials, with long-term disease control and favorable toxicity profiles [44, 45] . Overall, the combination of paclitaxel and immunotherapies holds the potential to improve the treatment outcomes of OSCC, but further research is needed to optimize treatment strategies. In our study, we utilized CiteSpace to identify burst keywords that can serve as significant indicators of research hotspots or frontiers. The evolution of these burst keywords over the past 20 years, as presented in Figure 9B, reveals the research field's focus on clinically evaluating the efficacy of various induction chemotherapy regimens for patients with OSCC. Based on this analysis, it has been determined that "phase III clinical trials" is the most prominent burst keyword as of 2014. These pivotal phase III clinical trials have played a crucial role in advancing the exploration of induction chemotherapy for OSCC. One notable study, the TAX 324 trial, demonstrated the effectiveness of combining paclitaxel with cisplatin and fluorouracil as an induction chemotherapy regimen for OSCC, resulting in a significant increase in the surgical resection rate [46] . Likewise, the RTOG 1016 study found that induction chemotherapy improves the overall survival of patients with OSCC [47] . Another potential induction chemotherapy regimen involves the combination of docetaxel, cisplatin, and 5-Fu with radiotherapy. The RADPLAT study compared the effectiveness of induction chemotherapy with paclitaxel and cisplatin to direct surgical resection in individuals with oral squamous carcinoma [48] . The findings of this study demonstrated that induction chemotherapy led to a decrease in tumor stage and an increase in the frequency of surgical removal. Strength and limitation Our study provides an initial methodical and logical assessment of the literature on OSCC induction chemotherapy research and its trends. In order to gain a comprehensive understanding, we employed various bibliometric software to analyze research hotspots from multiple perspectives. However, it is important to acknowledge the limitations of our study. Firstly, the literature we evaluated may not be exhaustive as we exclusively examined data from WoSCC and excluded data from other major search engines such as PubMed, Embase, Scopus, etc. Secondly, there might be some linguistic bias since we only included articles published in English. Lastly, due to the systematic settings of the bibliometric software, we were unable to conduct a thorough analysis of articles published before 2000 or after 2022 in this paper. Consequently, our study may not fully capture all the relevant studies on induction chemotherapy of OSCC. Role of the Funding Source This work was sponsored by the Interdisciplinary Program of Shanghai Jiao Tong University (YG2021QN60), Shanghai Sailing Program (21YF1423500 and 20YF1423300). Declarations Author Contribution WX and YWcontributed to the concept and were major contributors to writing the manuscript. HL and WX provided technical support and performed the histological examination.SL and WY designed the research study. All authors read and approved the final version of the manuscript. Data Availability Data is provided within the manuscript. References Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49. Gharat SA, Momin M, Bhavsar C. Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Crit Rev Ther Drug Carrier Syst. 2016;33:363-400. Marta GN, William WN, Feher O, Carvalho AL, Kowalski LP. Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives. Oral Oncol. 2015;51:1069-75. Zhong L-p, Zhang C-p, Ren G-x, Guo W, William WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744-51. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-15. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695-704. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257-64. Lee W-L, Chan IS, Wang P-H. Does a simple hematological examination predict the response and side effects in patients undergoing induction chemotherapy and/or neoadjuvant chemotherapy? J Chin Med Assoc. 2020;83:107-8. Hanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013;18:288-93. Wang J, Gong Z, Yu M. Bibliometric study on the knowledge graph of immunotherapy for head and neck cancer. Front Oncol. 2023;13:942777. van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111:1053-70. Zhong D, Luo S, Zheng L, Zhang Y, Jin R. Epilepsy Occurrence and Circadian Rhythm: A Bibliometrics Study and Visualization Analysis via CiteSpace. Front Neurol. 2020;11:984. Chang PMH, Chen PM, Chu PY, Wang LW, Tai SK, Tsai TL, et al. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;63:9-17. Miyazaki A, Kobayashi J, Yamamoto T, Kido Y, Takemura K, Abe M, et al. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma. Oral Oncol. 2008;44:471-6. Rivera F, Vega-Villegas ME, Lopez-Brea M, Isla D, Mayorga M, Galdos P, et al. Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62:253-61. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-27. Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, et al. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2013;31:744-51. Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, et al. Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease. MOLECULAR CANCER THERAPEUTICS. 2013;12:1112-21. Hu YJ, Sun WW, Zhao TC, Liu Y, Zhu DW, Wang LZ, et al. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer. ONCOLOGY LETTERS. 2020;20. Naruse T, Yanamoto S, Okuyama K, Ohmori K, Tsuchihashi H, Furukawa K, et al. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. PATHOLOGY & ONCOLOGY RESEARCH. 2020;26:735-42. Shirasu H, Yokota T, Kawakami T, Hamauchi S, Onozawa Y, Ogawa H, et al. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2020;25:1914-20. Wang J, Jia J, Zhou L. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis. NEOPLASMA. 2020;67:1279-92. Wen JQ, Xu HY, Liu RY, Chen QX, Dai YH, Xu Y. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients. CELLULAR AND MOLECULAR BIOLOGY. 2020;66:24-31. Yang YQ, Sun X, Yan JH, Li Q, Ni Y, Ma HQ. The effect of neo-adjuvant chemotherapy on the improvement of oral cancer patients and the predictive value of miR-182 on its efficacy. JOURNAL OF BUON. 2020;25:2017-22. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med. 2006;354:634-6. Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, et al. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol. 2022;13:815575. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265-72. Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21:327-33. Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735-43. Pignon J-P, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-55. Kirita T, Ohgi K, Shimooka H, Yamanaka Y, Tatebayashi S, Yamamoto K, et al. Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results. Oral Oncol. 1999;35:597-606. Kirita T, Yamanaka Y, Imai Y, Yamakawa N, Aoki K, Nakagawa Y, et al. Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg. 2012;41:421-8. Klug C, Berzaczy D, Voracek M, Millesi W. Preoperative chemoradiotherapy in the management of oral cancer: a review. J Craniomaxillofac Surg. 2008;36:75-88. Klug C, Berzaczy D, Voracek M, Nell C, Ploder O, Millesi W, et al. Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients. J Craniomaxillofac Surg. 2009;37:344-7. Eich HT, Löschcke M, Scheer M, Kocher M, Bongartz R, Wacker S, et al. Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity. Outcome of 134 patients. Strahlenther Onkol. 2008;184:23-9. Meng X, Lou Q-Y, Yang W-Y, Wang Y-R, Chen R, Wang L, et al. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond). 2021;41. Budach V. TPF sequential therapy: when and for whom? Oncologist. 2010;15 Suppl 3:13-8. Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol. 2017;28:2219-24. Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, et al. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019;30:471-7. Harada K, Ferdous T, Kobayashi H, Ueyama Y. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines. Int J Oncol. 2014;45:2439-45. Sawatani Y, Komiyama Y, Nakashiro K-I, Uchida D, Fukumoto C, Shimura M, et al. Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro. Int J Mol Sci. 2020;21. Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40. Chen T, Ning J, Campisi A, Dell'Amore A, Ciarrocchi AP, Li Z, et al. Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC: A Retrospective Study. Ann Thorac Surg. 2022;113:993-9. Hao W, Zhang J, Wang Y, Fang B, Jin S, Yuan J, et al. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis. Front Immunol. 2023;14:1175809. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12:153-9. Mehanna H, Rischin D, Wong SJ, Gregoire V, Ferris R, Waldron J, et al. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. J Clin Oncol. 2020;38:2552-7. Robbins KT, Kumar P, Regine WF, Wong FS, Weir AB, Flick P, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38:263-71. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4705733","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":335796880,"identity":"1cf3181d-5aeb-4fdc-90db-77d97c3e7cbd","order_by":0,"name":"Wei Xu","email":"","orcid":"","institution":"Jiangnan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Xu","suffix":""},{"id":335796881,"identity":"85a1a866-56c0-4df9-a616-066780793f35","order_by":1,"name":"Yifan Wu","email":"","orcid":"","institution":"Shanghai Ninth People's Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yifan","middleName":"","lastName":"Wu","suffix":""},{"id":335796882,"identity":"823abdec-5d10-4200-a0a9-a7ed1f20ad6a","order_by":2,"name":"Hao Lu","email":"","orcid":"","institution":"Shanghai Ninth People's Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hao","middleName":"","lastName":"Lu","suffix":""},{"id":335796883,"identity":"c94a4a02-40a6-4f12-af45-0c56f949c895","order_by":3,"name":"Wanlin Xu","email":"","orcid":"","institution":"Shanghai Ninth People's Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Wanlin","middleName":"","lastName":"Xu","suffix":""},{"id":335796884,"identity":"6a96a0de-3671-414e-b3cb-a2f5641f68fb","order_by":4,"name":"Shengwen Liu","email":"","orcid":"","institution":"Shanghai Ninth People's Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Shengwen","middleName":"","lastName":"Liu","suffix":""},{"id":335796885,"identity":"826452ed-b193-4c8e-ad63-d9a5925d7485","order_by":5,"name":"Wenjun Yang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABEUlEQVRIiWNgGAWjYBADZgYGxoYDCTxs9fzMzIcfEKmFufHBBxm+BMl2tjQDIi1ibzacYSOXYHCeR0ECnzqD42cPv+apuMNucLuxTZonxyzP+DAPgwFDjU00Ti1n8tKsec48Yza4cxCo5Uxasdlh3gMPGI6l5Tbg0nIgx8w4t+0ws8GNxDZp3p5jjNsO8yUYMDYcxq3l/Bugln8wLf/+M25u5jGQwKvlRo7x49wGsBag93nYEjcwE9AieeONGfOfY4eZJW8kAgOZh81Y4jAwkBPw+IXvfI7xxxk1h5P5bqQ/AEWlHH//4cMPPtTY4NSicICBDRQLyajCCTiUg4B8AwPzByBth0fNKBgFo2AUjHQAAAs3YlI95WTqAAAAAElFTkSuQmCC","orcid":"","institution":"Shanghai Ninth People's Hospital","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Wenjun","middleName":"","lastName":"Yang","suffix":""}],"badges":[],"createdAt":"2024-07-08 12:59:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4705733/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4705733/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":62328191,"identity":"83c276b0-3ada-47da-899b-3642e2fc9900","added_by":"auto","created_at":"2024-08-13 03:13:00","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":92548,"visible":true,"origin":"","legend":"\u003cp\u003eGlobal trend in publications and citations of induction chemotherapy of oral squamous cell carcinoma\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/a299259738aafc50bacb7b4d.png"},{"id":62328192,"identity":"84dabb92-05fa-4f02-bd0a-adbe49fd992a","added_by":"auto","created_at":"2024-08-13 03:13:00","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":35383,"visible":true,"origin":"","legend":"\u003cp\u003eThe distrbution of countries/regions in terms of publications\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/985858f45213c33fba48c479.png"},{"id":62327030,"identity":"ec4759f7-7e7f-4483-bb17-c3c9949426f3","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":24481,"visible":true,"origin":"","legend":"\u003cp\u003eThe distrbution of orgnazations in terms of publications\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/7a722e0395cd088b7bd10e54.png"},{"id":62327032,"identity":"6972443e-822d-4bfd-ae6c-1baf7681569d","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":150957,"visible":true,"origin":"","legend":"\u003cp\u003eCo-authorship analysis of top authors in relavant field. (A) Network visualization map of authors collaboration or (B) co-cited authors engaging in the IC of OSCC\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/6abf5319aef99f4c6abfaad0.png"},{"id":62327033,"identity":"b9cb1ebf-3c7c-4a8a-bcc0-569c24270cac","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":189418,"visible":true,"origin":"","legend":"\u003cp\u003eNetwork visualization map of academic journals (A) or co-cited journals (B) publishing research on IC of OSCC\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/08d7e3e15e23272faea60cd3.png"},{"id":62327036,"identity":"993139dc-3cd4-4dab-b1b1-e0e9cc5d7043","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":227346,"visible":true,"origin":"","legend":"\u003cp\u003eThe dual-map overlay of journals related to IC of OSCC\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/960e745b5c0e1b0757405a3d.png"},{"id":62327037,"identity":"458ed804-497a-45a1-a4b8-933f7b81fe94","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":188964,"visible":true,"origin":"","legend":"\u003cp\u003e(A) Network visualization map of the top 21 co-cited references. (B) Timeline view of all co-cited references.\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/df5ef4d81e5dd7ccda1a3cb2.png"},{"id":62327038,"identity":"31d690e9-3bbc-4375-b054-0191892a01f6","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":269852,"visible":true,"origin":"","legend":"\u003cp\u003eTop 10 references with strongest citation bursts.\u003c/p\u003e","description":"","filename":"8.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/93490a038b3b370351d38b1b.png"},{"id":62327035,"identity":"05863b06-f658-4247-90e1-9d684d9daf99","added_by":"auto","created_at":"2024-08-13 03:05:00","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":196440,"visible":true,"origin":"","legend":"\u003cp\u003e(A) Density visualization map of the most frequency used keywords. (B) Top 10 keywords with strongest citation bursts.\u003c/p\u003e","description":"","filename":"9.png","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/3cb59f968c2aa2a2627d4606.png"},{"id":64082517,"identity":"defebafb-5c6b-448f-86ff-a29864837294","added_by":"auto","created_at":"2024-09-06 10:50:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1956789,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4705733/v1/5dd0ab96-69a7-49e5-8602-eb104ed4c375.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022 by Bioinformatics and Cancer Database Analysis","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eOral squamous cell carcinoma (OSCC) is a prevalent cancer type that affects the oral cavity, leading to a high mortality rate and imposing a significant healthcare burden globally\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e. Current treatment options for OSCC, including surgery, radiotherapy, and chemotherapy, have limited efficacy, particularly in advanced stages of the disease. Furthermore, these treatments often result in severe side effects and a diminished quality of life for patients\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn recent years, there has been growing interest in the development of targeted therapies for OSCC, such as induction chemotherapy. Induction chemotherapy involves administering drugs prior to the primary treatment to shrink the tumor and enhance its response to subsequent therapy\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e. This approach aims to increase the chances of a successful outcome and improve the overall survival rate of OSCC patients. Preclinical and clinical studies have shown promising results with the use of induction chemotherapy in OSCC\u003csup\u003e[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e. Various chemotherapeutic agents, including cisplatin, docetaxel, and 5-fluorouracil, have been used alone or in combination to induce tumor regression\u003csup\u003e[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]\u003c/sup\u003e. The success of induction chemotherapy lies in its ability to enhance the sensitivity of OSCC cells to radiation or surgery, thereby increasing the effectiveness of subsequent treatments\u003csup\u003e[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/sup\u003e. However, despite its potential benefits, there are several challenges that need to be addressed, such as chemotherapy drug resistance, toxic side effects, and the absence of reliable biomarkers for patient selection and treatment response monitoring\u003csup\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/sup\u003e. Additionally, optimizing the timing, dosage, and duration of induction chemotherapy is crucial to maximize its therapeutic benefits\u003csup\u003e[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eBibliometric studies play a crucial role in evaluating the scientific output and impact of research in various fields\u003csup\u003e[\u003cspan additionalcitationids=\"CR11\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/sup\u003e. Recently, there has been a significant increase in publications related to induction chemotherapy in OSCC, emphasizing the importance of identifying key contributors, institutions, and countries involved in this research area. However, there has been a lack of specific bibliometric studies focusing on the knowledge graph of induction chemotherapy in OSCC. This study aims to conduct a comprehensive bibliometric analysis of the literature from 2000 to 2022, examining induction chemotherapy in OSCC. The findings will contribute to a better understanding of the research landscape and guide future research endeavors in this field.\u003c/p\u003e"},{"header":"2. Materials and methods","content":"\u003cp\u003e \u003cb\u003eData sources and search strategies\u003c/b\u003e \u003c/p\u003e \u003cp\u003eA systematic approach was employed to conduct a comprehensive bibliometric study on induction chemotherapy (IC) in oral squamous cell carcinoma (OSCC) and identify relevant publications. The Web of Science Core Collection (WoSCC) database was searched using a carefully designed search strategy. Two search lists were used, combining relevant keywords with the 'and' operator. The first list covered terms related to oral squamous cell carcinoma, including 'oral squamous cell carcinoma,' 'oral cancer,' and 'OSCC.' The second list included terms associated with induction chemotherapy, such as 'induction chemotherapy' and 'neoadjuvant chemotherapy.' The search was limited to English-written articles published between January 1, 2000, and December 31, 2022. Inclusion criteria were established for article selection, which consisted of studies focusing on induction chemotherapy in oral squamous cell carcinoma, original research or literature reviews, and availability of full-text articles. Two authors (Xu Wand Wu YF) independently conducted the search in the WoSCC database, downloading the relevant literature in TXT format, which included titles, keywords, author information, abstracts, references, etc. Any discrepancies encountered during the search process were resolved through discussion or consultation with third-party experts (Liu SW and Yang WJ).\u003c/p\u003e \u003cp\u003e \u003cb\u003eBibliometrics analysis and visualization\u003c/b\u003e \u003c/p\u003e \u003cp\u003eFollowing the initial search and screening process, the selected articles underwent meticulous examination to extract significant bibliometric data. The extracted data encompassed publication year, author names, affiliations, journal titles, citation counts, and collaboration networks. Microsoft Excel 2019 was employed to generate comprehensive reports on annual publications and citations. For the purposes of bibliometric and visual analysis, CiteSpace (6.2.R4) and VOSviewer (1.6.19) were utilized. These tools facilitated the identification of countries, institutions, authors, journals, references, and keywords, as well as the exploration of network characteristics and keyword bursts. VOSviewer was particularly useful in investigating collaborative networks among organizations, countries, journals, co-cited journals, authors, co-cited authors, co-cited references, and keywords. The size of nodes in the collaborative networks denoted their frequency of occurrence or reference. CiteSpace was employed to detect keyword and reference bursts, utilizing specific parameters such as a time span of 2000\u0026ndash;2022 (slice length\u0026thinsp;=\u0026thinsp;1), selection criteria of g-index (k\u0026thinsp;=\u0026thinsp;5), link retaining factor (LRF\u0026thinsp;=\u0026thinsp;3), look back years (LBY\u0026thinsp;=\u0026thinsp;5), and e for top N (e\u0026thinsp;=\u0026thinsp;1). Additionally, links were determined based on cosine strength within slices, and a minimum duration of 1 was established. Consequently, a timeline view of co-cited references was generated, along with a dual-map overlay highlighting the interrelations between journals in the induction chemotherapy of OSCC.\u003c/p\u003e"},{"header":"3. Results","content":"\u003cp\u003e \u003cb\u003eGlobal growth trend in publication outputs and citations\u003c/b\u003e \u003c/p\u003e \u003cp\u003eA search of the Web of Science (WOS) database identified a total of 227 articles published between 2000 and 2022 on induction chemotherapy for oral squamous cell carcinoma. As depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e, there was a significant fluctuation in the number of published articles, with an overall upward trend. Prior to 2012, the annual article count remained below 10, reaching a low of just one article in 2007. However, after 2013, the annual article count exceeded 10, peaking in 2014 with 19 articles, before gradually declining to around 12 articles per year. Following 2020, there was a gradual increase in the number of articles, resulting in a tie for the highest number of articles in 2021 and 2022, with 21 articles each. Overall, the total number of research papers in this field remains relatively low. However, it is noteworthy that the citation rate of articles related to induction chemotherapy for oral squamous cell carcinoma has consistently increased over time, indicating a growing interest among international scholars in this research area.\u003c/p\u003e \u003cp\u003e \u003cb\u003eDistribution of countries/regions and institutions\u003c/b\u003e \u003c/p\u003e \u003cp\u003eA total of 227 articles were collected from 28 different countries or regions. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e displays the top ten countries with the highest number of articles. China and the United States rank first (n\u0026thinsp;=\u0026thinsp;46, 20.26%), followed by Japan (n\u0026thinsp;=\u0026thinsp;32, 14.10%). However, when considering citations, the United States takes the lead (n\u0026thinsp;=\u0026thinsp;3387), followed by France (n\u0026thinsp;=\u0026thinsp;2090) and China (n\u0026thinsp;=\u0026thinsp;727). Figure\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e illustrates the close and extensive collaborations between countries, especially between the US and China.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTop 10 countries/regions publishing research articles on induction chemotherapy for OSCC\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCountry/Regions\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePublications\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCitations\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e727\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3387\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e289\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIndia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e263\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGermany\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e624\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTaiwan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e174\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e295\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFrance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e2090\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBrazil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e116\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHungary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eThese articles originated from 372 institutions, including Shanghai Jiao Tong University (n\u0026thinsp;=\u0026thinsp;26, 11.45%) in China, The University of Texas MD Anderson Cancer Center (n\u0026thinsp;=\u0026thinsp;13, 5.73%) in the United States, and Tata Memorial Hospital (n\u0026thinsp;=\u0026thinsp;11) in India, all of which have contributed more than 10 publications, as shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. Figure\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e exhibits the inter-institutional collaborations, highlighting the close partnerships between Shanghai Jiao Tong University and various domestic and international institutions, such as The University of Texas MD Anderson Cancer Center and the Shanghai Key Laboratory of Stomatology.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTop 5 institutions publishing research articles on induction chemotherapy for OSCC\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eInstitution\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePublications\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCitations\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eShanghai JiaoTong University\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e575\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThe University of Texas MD Anderson Cancer Center\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e416\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTata Memorial Hospital\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e180\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUniversity of Cologne\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e130\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMalabar Cancer Centre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eShanghai Key Laboratory of Stomatology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAnalysis of authors and co-cited authors\u003c/p\u003e \u003cp\u003eA total of 1609 authors participated in studies concerning induction chemotherapy for oral squamous cell carcinoma. Among them, four authors from China, namely Zhong Laiping (n\u0026thinsp;=\u0026thinsp;13), Zhang Zhiyuan (n\u0026thinsp;=\u0026thinsp;12), Zhang Chenping (n\u0026thinsp;=\u0026thinsp;11), and Li Jiang (n\u0026thinsp;=\u0026thinsp;10), had more than 10 individual publications (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Furthermore, as depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA, the nodes in the graph represent the number of publications, with Zhong Laiping and Zhang Chenping having the largest node. This suggests that these two authors were in communication and collaboration with other authors including Zhu Dongwang, Zhao Tongchao, Ju Wutong, Guo Wei, Ren Guoxin.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTop 10 authors and co-cited authors involved in OSCC induction chemotherapy research\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAuthor\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCounts\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCitations\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCo-cited Author\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eCitations\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZhong Laiping\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e412\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePosner MR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e104\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZhang Zhiyuan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e363\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eVermorken JB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e104\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZhang Chenping\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e359\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eZhong LP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e89\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLi Jiang\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e308\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePignon JP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e86\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWang Lizhen\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e308\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eLicitra L\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLiu Ying\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e184\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eHitt R\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGuo Wei\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e255\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eForastiere AA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e59\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRen Guoxin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCohen EEW\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e57\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZhu Dongwang\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eVokes EE\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e57\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKov\u0026aacute;cs \u0026Aacute;F\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e121\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eBernier J\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eVanita Noronha\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eHaddad RI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eVijay Maruti Patil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e153\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKumar Prabhash\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAmong the 3885 co-cited authors, Vermorken JB and Posner MR tied for first place with a frequency of 104 citations. They are followed by Zhong Laiping (n\u0026thinsp;=\u0026thinsp;89) and Pignon JP (n\u0026thinsp;=\u0026thinsp;86) (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Lastly, we identified the top 40 authors with over 20 citations and constructed a network of co-cited authors (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB).\u003c/p\u003e \u003cp\u003e \u003cb\u003eAnalysis of journals and co-cited journals\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAccording to the data presented, a total of 111 journals have published literature related to induction chemotherapy for oral squamous cell carcinoma. The journal with the highest number of publications on this topic is Oral Oncology, with 24 articles. It is closely followed by Head and Neck - Journal for the Sciences and Specialties of the Head and Neck, which has published 11 articles, and Indian Journal of Cancer with 8 articles (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e). When considering the impact factor of the journals, the top three journals with the highest impact factors are Annals of Oncology from the Netherlands (IF\u0026thinsp;=\u0026thinsp;50.5) with six publications, Journal of Clinical Oncology (IF\u0026thinsp;=\u0026thinsp;45.3) with 4 publications, and Cancer (IF\u0026thinsp;=\u0026thinsp;6.2) from the USA with five publications. The majority of the top ten journals with the highest impact factors are American journals, accounting for 42.86% of the total journals and taking the first place in the list. Creating a journal network by filtering out the journals with more than four publications, it was observed that Oral Oncology had active citation with Journal of Clinical Oncology, Annals of Oncology, and Head and Neck - Journal for the Sciences and Specialties of the Head and Neck (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTop 10 journals by several publications and co-citations\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJournal\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePublications\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCountry\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eIF\u003c/p\u003e \u003cp\u003e(2022)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eCo-cited Journal\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCitation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eCountry\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003eIF\u003c/p\u003e \u003cp\u003e(2022)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOral Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEngland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eJournal of Clinical Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e906\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e45.3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHead and Neck-Journal for the Sciences and Specialties of the Head and Neck\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNew England Journal of Medicine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e415\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e158.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIndian Journal of Cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIndia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eInternational Journal of Radiation Oncology Biology Physics\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e363\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e6.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnnals of Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNetherland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eOral Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e362\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eEngland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e4.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnticancer Research\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGreece\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eAnnals of Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e263\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eNetherland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e50.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBMC Cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEngland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eHead and Neck-Journal for the Sciences and Specialties of the Head and Neck\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e261\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e2.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e6.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eCancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e213\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e6.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eRadiotherapy and Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e189\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eNetherland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e5.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCancer Chemotherapy and Pharmacology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eLancet Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e133\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eEngland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e51.1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJournal of Clinical Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e45.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eBritish Journal of Cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e127\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eEngland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c10\"\u003e \u003cp\u003e8.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJournal of Oral Pathology \u0026amp; Medicine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDenmark\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOncology Letters\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGreece\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOncotarget\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e provides information on co-cited journals, showing that there are four journals with more than 300 citations. Journal of Clinical Oncology ranks first with 906 citations, followed by New England Journal of Medicine (415 citations), International Journal of Radiation Oncology Biology Physics (363 citations), and Oral Oncology (362 citations). These highly cited journals have different impact factors, with New England Journal of Medicine ranking highest (IF\u0026thinsp;=\u0026thinsp;158.4). Figure\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB illustrates the journal network constructed with several co-cited journals meeting a minimum 30 of citations criteria. It portrays the co-citation relationship among journals, and the most cited journals in this network are Journal of Clinical Oncology, Annals of Oncology, Cancer, and International Journal of Radiation Oncology Biology Physics. These journals have a strong relationship in terms of citations.\u003c/p\u003e \u003cp\u003eThe dual map overlay of journals illustrates the citation relationships between the citing journals (on the left) and the co-cited journals (on the right) (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e). The primary citation paths are represented by yellow and two green paths. These paths indicate that studies published in Molecular/Biology/Genetics journals were predominantly cited by articles in Molecular/Biology/Immunology and Medicine/Medical/Clinical journals. On the other hand, studies published in Health/Nursing/Medical journals were predominantly cited by literature in Medicine/Medical/Clinical journals (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cb\u003eAnalysis of co-cited references and reference with citation burst\u003c/b\u003e \u003c/p\u003e \u003cp\u003eFrom 2000 to 2022, a total of 5250 co-cited references were identified in the research on induction chemotherapy for oral squamous cell carcinoma. Eight out of the top ten most highly cited articles exceeded 30 citations (Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e). The article with the highest number of citations was \"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer\" by Vermorken JB, published in the New England Journal of Medicine (IF\u0026thinsp;=\u0026thinsp;158.5) in 2007. Pignon JP had two articles in the top ten, published in Lancet (IF\u0026thinsp;=\u0026thinsp;168.9) in 2000 and in Radiotherapy and Oncology (IF\u0026thinsp;=\u0026thinsp;5.7) in 2009. A co-citation network was constructed using 21 articles with more than 20 citations (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eA). Vermorken JB's 2007 article in the New England Journal of Medicine had strong co-citation relationships with Vermorken JB's 2007 article in the same journal and Haddad R's 2013 article in Lancet Oncology. Additionally, a timeline displaying the co-cited references was generated (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eB). The timeline view is a data visualization method that combines clustering and time slicing techniques. The clustering labels are sorted based on their appearance order. The main terms of the co-cited references ranged from \"#5 radiochemotherapy\" in 2000 to \"#0 paclitaxel\" from 2015 to 2021.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTop 10 co-cited references on research of induction chemotherapy for OSCC\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRank\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTitle\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJournal\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFirst author\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYear\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCitations\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNew England journal of\u003c/p\u003e \u003cp\u003emedicine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eJan B Vermorken\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2007\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e81\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCisplatin and fluorouracil alone or with docetaxel in head and neck cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNew England journal of\u003c/p\u003e \u003cp\u003emedicine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMarshall R Posner\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2007\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJournal of Clinical Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eLisa Licitra\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2003\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRandomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJournal of Clinical Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eLai-ping Zhong\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2013\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eInduction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLancet Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRobert Haddad\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2013\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e47\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLancet\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eJ P Pignon\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRadiotherapy and Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eJ P Pignon\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2009\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePhase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJournal of Clinical Oncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEzra E W Cohen\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2014\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e38\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePhase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJNCI-Journal of the National Cancer Institute\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eA Paccagnella\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1994\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePostoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNew England Journal of Medicine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eJacques Bernier\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e#10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLarynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJNCI-Journal of the National Cancer Institute\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eJ L Lefebvre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1996\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eInduction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNew England Journal of Medicine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGregory T Wolf\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1991\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e presents the highly cited references, which are those frequently cited by scholars in the field over a certain period. We utilized CiteSpace software to analyze the top ten strong citation bursts, where the red bars represent the periods of intense citation activity. The earliest citation burst occurred in 2002, and the latest burst was observed in 2022. The article with the strongest burst was \"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer,\" which spanned from 2015 to 2019. It was followed by the article \"Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma\" from 2013 to 2018, and \"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial\" from 2014 to 2018. Overall, the burst intensities of these articles ranged from 5.16 to 8.76, and the durations of the bursts varied from 2 to 5 years.\u003c/p\u003e \u003cp\u003e \u003cb\u003eAnalysis of keywords\u003c/b\u003e \u003c/p\u003e \u003cp\u003eA density visualization of keywords was constructed using VOSviewer (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eA). The yellow portion represents keywords with high frequency, while CiteSpace (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eB) was utilized to identify the top ten keywords with the strongest citation bursts. Figure\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eB displays the period from 2000 to 2022 using the blue line, while the red line depicts the period associated with each burst keyword. The earliest burst keyword, \"head and neck cancer,\" emerged in 2003 with a strength of 3. 79. In recent years, the prominent keywords are primarily \"phase III trial\" (strength\u0026thinsp;=\u0026thinsp;4.36, 2014\u0026ndash;2020), \"surgery\" (strength\u0026thinsp;=\u0026thinsp;3.47, 2018\u0026ndash;2022), and \"concurrent chemoradiotherapy\" (strength\u0026thinsp;=\u0026thinsp;2.3, 2019\u0026ndash;2022).\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003e\u003cstrong\u003eGeneral Information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe conducted a systematic review of articles published between 2000 and 2022 that focused on induction chemotherapy for oral squamous cell carcinoma. After excluding studies that did not meet the predefined screening criteria, our analysis comprised 227 English-language articles from 111 journals and 5,250 co-cited references originating from 372 institutions across 28 countries/regions.\u003c/p\u003e\n\u003cp\u003eOur findings indicate a gradual, albeit fluctuating, increase in research on induction chemotherapy for oral squamous cell carcinoma since 2000, although the overall publication output remains relatively low. Notably, three significant shifts emerged in 2008, 2013, and 2020. These turning points were characterized by substantial increases in publication volume compared to the preceding year. This can be attributed to the exploration of the efficacy and safety of various chemotherapy drugs, such as cisplatin and 5-fluorouracil, in multiple studies in 2008, along with corresponding phase I and II clinical trials\u003csup\u003e[13-16]\u003c/sup\u003e. In 2013, the phase III clinical trial of TPF regimen for oral squamous cell carcinoma by Zhong Laiping further advanced research in this field\u003csup\u003e[17, 18]\u003c/sup\u003e. In 2020, molecular biology and immunotherapy contributed to the development of personalized chemotherapy based on molecular targets and combination immunotherapy, bringing oral squamous cell carcinoma treatment back into the public\u003csup\u003e[19-24]\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eChina and the United States shared the top spot in terms of publication count. Notably, three of the top four countries are from Asia (China, India, and Japan), reflecting the high incidence of oral cancer in the region. The distribution of institutions matches the distribution of countries/regions. The top three institutions are from China, USA, and India. Close collaboration between countries/regions and institutions was observed, particularly between China and the United States, as well as multi-party collaborations centered around China and the United States.\u003c/p\u003e\n\u003cp\u003eAmong the top ten active authors in terms of publication volume, each author has published at least five articles, and the top four authors have published more than ten articles, with citation counts of more than 300 for all articles. Among these thirteen prolific authors, twelve from Asia, comprising nine Chinese scientists affiliated with Shanghai Jiao Tong University and three researchers from India's Tata Memorial Hospital. This finding suggests that Asian researchers have played an important role and made significant contributions to the research on induction chemotherapy for oral squamous cell carcinoma.\u003c/p\u003e\n\u003cp\u003eCo-cited authors assume a pivotal role in this field. Among the top ten co-cited authors, only Posner MR and Vermorken JB have been co-cited more than 100 times (co-citations = 104). Zhong Laiping, who ranks first in terms of publication volume, ranks third with 89 co-citations. These three authors have conducted clinical trials on PF and TPF induction chemotherapy for oral squamous cell carcinoma. In addition, Posner MR and Vermorken JB further investigated the efficacy of induction chemotherapy regimens in combination with cetuximab, while Zhong Laiping conducted a pilot study on the neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib in 2022, opening new avenues for research in induction chemotherapy for oral squamous cell carcinoma\u003csup\u003e[5, 6, 16, 17, 25]\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eThe top ten journals accounted for only 94 papers, representing 41% of the total publications in this research domain. \u003cem\u003eOral Oncology\u003c/em\u003e claimed the top position with 24 publications, followed by \u003cem\u003eHead and Neck-Journal for the Sciences and Specialties of the Head and Neck\u003c/em\u003e with 11 publications and \u003cem\u003eIndian Journal of Cancer\u003c/em\u003e with eight publications. This indicates that these journals are particularly interested in articles related to induction chemotherapy research of oral squamous cell carcinoma. This data will help future scientists in selecting journals for submitting manuscripts in terms of this field.\u003c/p\u003e\n\u003cp\u003eFurthermore, following a thorough analysis of authorship, co-cited authors, and co-cited references, we identified Zhong Laiping as the sole researcher present in all three categories. This suggests that he is an accomplished author in the field, and his team is an excellent research team. His team has the potential to be excellent collaborators for researchers.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eKnowledge base\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhen two publications are co-cited by a third publication, it establishes a co-citation relationship. The significance of a document in a specific field increases as it receives more citations. This reflects the knowledge base and primary concerns of researchers in that field\u003csup\u003e[26]\u003c/sup\u003e. Table 5 presents the top ten most cited articles, comprising 11 publications that originate from renowned international journals with high impact factors. Among these, nine articles are clinical trials, while the remaining two are meta-analyses. These clinical trials primarily investigate the selection of induction chemotherapy regimens for advanced oral squamous cell carcinoma and conduct phase II or III clinical trials to assess the effectiveness of induction chemotherapy. The first clinical trial conducted in 1994 showed that neoadjuvant chemotherapy reduced the incidence of distant metastases in operable patients and improved local control, distant metastasis incidence, complete remission, and overall survival in inoperable patients\u003csup\u003e[27]\u003c/sup\u003e (#9). The most cited article, a phase III clinical trial by Jan B Vermorken in 2007\u003csup\u003e[6]\u003c/sup\u003e (#1), compared the efficacy of two induction chemotherapy regimens (TPF and PF) in locally advanced, unresectable oral squamous cell carcinoma. It found that the TPF regimen significantly improved progression-free survival and overall survival compared to the PF regimen. In the same year, Marshall R Posner conducted a phase III clinical trial\u003csup\u003e[5]\u003c/sup\u003e (#2) that also concluded that the TPF induction chemotherapy regimen in combination with radiotherapy was more effective than the PF regimen. However, a study by Robert Haddad in 2013\u003csup\u003e[7]\u003c/sup\u003e (#5) compared the efficacy of concurrent chemoradiotherapy after induction chemotherapy with TPF versus concurrent cisplatin-based chemoradiotherapy alone in patients with locally advanced unresectable head and neck cancer. It found that preoperative induction chemotherapy with TPF did not significantly improve patient survival. Another study by Zhong Laiping\u003csup\u003e[4]\u003c/sup\u003e (#4) suggested that in patients with respectable stage III or IV oral squamous cell carcinoma, TPF-induced chemotherapy was not effective in improving survival compared to surgery. Similarly, Lisa Licitra's study\u0026nbsp;\u003csup\u003e[28]\u003c/sup\u003e (#3) found that adding TPF chemotherapy to standard surgery did not improve survival. A subsequent study by Ezra E W Cohen\u003csup\u003e[29]\u003c/sup\u003e (#8) concluded that induction chemotherapy did not significantly improve overall survival in patients with advanced N2, N3 head and neck squamous cell carcinoma compared to chemoradiotherapy alone. Based on these co-citation relationships, it can be inferred that the efficacy of induction chemotherapy regimens for advanced oral squamous cell carcinoma is a topic of interest and discussion among researchers in the field.\u003c/p\u003e\n\u003cp\u003eTwo meta-analyses investigating the effectiveness of chemotherapy in the treatment of head and neck squamous cell carcinoma indicated that concurrent chemotherapy was more beneficial for patients compared to induction chemotherapy\u003csup\u003e[30]\u003c/sup\u003e (#7). However, a previous study published in The Lancet presented opposing findings, suggesting that chemotherapy had limited impact on patient survival\u003csup\u003e[31]\u003c/sup\u003e (#6).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOverall, these ten highly cited papers provide a comprehensive evaluation and analysis of the efficacy of induction chemotherapy for advanced oral squamous cell carcinoma. Additionally, they delve into the exploration and enhancement of induction chemotherapy regimens. Furthermore, the application of co-citation analysis furnishes us with valuable insights into the evolution of the knowledge structure pertaining to induction chemotherapy for oral squamous cell carcinoma.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch frontiers\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo explore and identify new areas of research in induction chemotherapy for oral squamous cell carcinoma, we utilized CiteSpace to analyze co-cited references. Figure 7B demonstrates that earlier studies conducted between 2000 and 2005 mainly focused on investigating the effectiveness of sequential treatment involving chemotherapy combined with radiotherapy for OSCC, specifically referred to as \"#5 radiochemotherapy\". Notably, preoperative concurrent chemoradiotherapy followed by radical surgery has yielded promising long-term outcomes for advanced squamous cell carcinoma of the oral cavity. Studies conducted by Kirita et al. showcased high response rates both clinically and pathologically, along with impressive survival rates at 5 and 10 years\u003csup\u003e[32, 33]\u003c/sup\u003e. This treatment regimen also resulted in notable clinical tumor response rates, acceptable acute toxicity, and minimal late therapeutic complications\u003csup\u003e[33]\u003c/sup\u003e. Individuals who achieved favorable histopathological responses exhibited superior survival rates when compared to those with substantial residual tumors\u003csup\u003e[34]\u003c/sup\u003e. Furthermore, Klug et al.'s study discovered that preoperative radiochemotherapy combined with radical surgery led to a 5-year overall survival probability of 53.9%, along with a 5-year local control probability of 70.2%\u003csup\u003e[35]\u003c/sup\u003e. Similarly, Eich et al. reported positive outcomes with neoadjuvant radiochemotherapy followed by radical surgery, demonstrating an overall survival of 65% at 2 years and 45% at 5 years\u003csup\u003e[36]\u003c/sup\u003e. These findings strongly indicate that preoperative concurrent chemoradiotherapy followed by radical surgery serves as an effective and safe treatment option for advanced oral cavity squamous cell carcinoma.\u003c/p\u003e\n\u003cp\u003eCurrently, the primary attention is directed towards the selection of induction chemotherapy regimens for OSCC. Additionally, new approaches involving the combination of induction chemotherapy and immunotherapy, such as \"#0 paclitaxel\", are under investigation. Paclitaxel (PTX), a member of the taxane family, has shown broad antitumor activity and is commonly used in the treatment of various solid tumors, including OSCC. Its primary mode of action is by disrupting microtubule dynamics, leading to mitotic arrest and eventual cell death\u003csup\u003e[37]\u003c/sup\u003e. Another taxane chemotherapeutic agent, docetaxel, is commonly used for induction chemotherapy in OSCC as a TPF regimen, which includes 5-fluorouracil and cisplatin, since it is a microtubule inhibitor like PTX. Data from randomized trials suggest that TPF sequential therapy may be a viable alternative to concurrent chemoradiotherapy in certain patients. TPF therapy is generally well-tolerated, but does have a higher incidence of hematologic adverse events, including neutropenia and complications linked with neutropenia, compared to PF therapy\u003csup\u003e[38]\u003c/sup\u003e. PTX has demonstrated broad antitumor activity as a stand-alone treatment or in combination with other chemotherapy agents. For instance, several scholars have conducted clinical studies in recent years, concentrating on the effectiveness of combining cetuximab with traditional TPF chemotherapy in advanced OSCC\u003csup\u003e[39, 40]\u003c/sup\u003e. Additionally, some basic experiments have confirmed that the combination of PTX and cetuximab boosts the antitumor activity of OSCC through inhibition of the NF-κB activity\u003csup\u003e[41]\u003c/sup\u003e. Yuta Sawatani et al. discovered that PTX increased the anti-cancer impact of cetuximab in vitro by improving antibody-dependent cytotoxicity (ADCC) in OSCC cells\u003csup\u003e[42]\u003c/sup\u003e. \u0026nbsp; Tumor immunotherapy generates immune responses against tumors by enhancing the body's immune system. Recently, progress has been made in understanding the potential application of classical drugs in tumor immunotherapy. Numerous studies have shown that paclitaxel can directly kill tumor cells and modulate various immune cells, such as effector T cells, dendritic cells (DCs), natural killer cells (NK cells), regulatory T cells (Tregs), and macrophages\u003csup\u003e[43]\u003c/sup\u003e. Paclitaxel can inhibit the function of Tregs and reverse tumor immune escape. Therefore, the combination of paclitaxel and immunotherapy can enhance treatment efficacy\u003csup\u003e[43]\u003c/sup\u003e. Recent research has focused on combining paclitaxel with immunotherapies to improve treatment outcomes. The combination therapy of paclitaxel and immune checkpoint inhibitors has shown promising efficacy signals in clinical trials, with long-term disease control and favorable toxicity profiles\u003csup\u003e[44, 45]\u003c/sup\u003e. Overall, the combination of paclitaxel and immunotherapies holds the potential to improve the treatment outcomes of OSCC, but further research is needed to optimize treatment strategies.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;In our study, we utilized CiteSpace to identify burst keywords that can serve as significant indicators of research hotspots or frontiers. The evolution of these burst keywords over the past 20 years, as presented in Figure 9B, reveals the research field's focus on clinically evaluating the efficacy of various induction chemotherapy regimens for patients with OSCC. Based on this analysis, it has been determined that \"phase III clinical trials\" is the most prominent burst keyword as of 2014. These pivotal phase III clinical trials have played a crucial role in advancing the exploration of induction chemotherapy for OSCC. One notable study, the TAX 324 trial, demonstrated the effectiveness of combining paclitaxel with cisplatin and fluorouracil as an induction chemotherapy regimen for OSCC, resulting in a significant increase in the surgical resection rate\u003csup\u003e[46]\u003c/sup\u003e. Likewise, the RTOG 1016 study found that induction chemotherapy improves the overall survival of patients with OSCC\u003csup\u003e[47]\u003c/sup\u003e. Another potential induction chemotherapy regimen involves the combination of docetaxel, cisplatin, and 5-Fu with radiotherapy. The RADPLAT study compared the effectiveness of induction chemotherapy with paclitaxel and cisplatin to direct surgical resection in individuals with oral squamous carcinoma\u003csup\u003e[48]\u003c/sup\u003e. The findings of this study demonstrated that induction chemotherapy led to a decrease in tumor stage and an increase in the frequency of surgical removal.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStrength and limitation\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOur study provides an initial methodical and logical assessment of the literature on OSCC induction chemotherapy research and its trends. In order to gain a comprehensive understanding, we employed various bibliometric software to analyze research hotspots from multiple perspectives. However, it is important to acknowledge the limitations of our study. Firstly, the literature we evaluated may not be exhaustive as we exclusively examined data from WoSCC and excluded data from other major search engines such as PubMed, Embase, Scopus, etc. Secondly, there might be some linguistic bias since we only included articles published in English. Lastly, due to the systematic settings of the bibliometric software, we were unable to conduct a thorough analysis of articles published before 2000 or after 2022 in this paper. Consequently, our study may not fully capture all the relevant studies on induction chemotherapy of OSCC.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRole of the Funding Source\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was sponsored by the Interdisciplinary Program of Shanghai Jiao Tong University (YG2021QN60), Shanghai Sailing Program (21YF1423500 and 20YF1423300).\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eWX and YWcontributed to the concept and were major contributors to writing the manuscript. HL and WX provided technical support and performed the histological examination.SL and WY designed the research study. All authors read and approved the final version of the manuscript.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eData is provided within the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.\u003c/li\u003e\n \u003cli\u003eGharat SA, Momin M, Bhavsar C. Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Crit Rev Ther Drug Carrier Syst. 2016;33:363-400.\u003c/li\u003e\n \u003cli\u003eMarta GN, William WN, Feher O, Carvalho AL, Kowalski LP. Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives. Oral Oncol. 2015;51:1069-75.\u003c/li\u003e\n \u003cli\u003eZhong L-p, Zhang C-p, Ren G-x, Guo W, William WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744-51.\u003c/li\u003e\n \u003cli\u003ePosner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-15.\u003c/li\u003e\n \u003cli\u003eVermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695-704.\u003c/li\u003e\n \u003cli\u003eHaddad R, O\u0026apos;Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257-64.\u003c/li\u003e\n \u003cli\u003eLee W-L, Chan IS, Wang P-H. Does a simple hematological examination predict the response and side effects in patients undergoing induction chemotherapy and/or neoadjuvant chemotherapy? J Chin Med Assoc. 2020;83:107-8.\u003c/li\u003e\n \u003cli\u003eHanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013;18:288-93.\u003c/li\u003e\n \u003cli\u003eWang J, Gong Z, Yu M. Bibliometric study on the knowledge graph of immunotherapy for head and neck cancer. Front Oncol. 2023;13:942777.\u003c/li\u003e\n \u003cli\u003evan Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111:1053-70.\u003c/li\u003e\n \u003cli\u003eZhong D, Luo S, Zheng L, Zhang Y, Jin R. Epilepsy Occurrence and Circadian Rhythm: A Bibliometrics Study and Visualization Analysis via CiteSpace. Front Neurol. 2020;11:984.\u003c/li\u003e\n \u003cli\u003eChang PMH, Chen PM, Chu PY, Wang LW, Tai SK, Tsai TL, et al. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;63:9-17.\u003c/li\u003e\n \u003cli\u003eMiyazaki A, Kobayashi J, Yamamoto T, Kido Y, Takemura K, Abe M, et al. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma. Oral Oncol. 2008;44:471-6.\u003c/li\u003e\n \u003cli\u003eRivera F, Vega-Villegas ME, Lopez-Brea M, Isla D, Mayorga M, Galdos P, et al. Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62:253-61.\u003c/li\u003e\n \u003cli\u003eVermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-27.\u003c/li\u003e\n \u003cli\u003eZhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, et al. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2013;31:744-51.\u003c/li\u003e\n \u003cli\u003eZhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, et al. Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease. MOLECULAR CANCER THERAPEUTICS. 2013;12:1112-21.\u003c/li\u003e\n \u003cli\u003eHu YJ, Sun WW, Zhao TC, Liu Y, Zhu DW, Wang LZ, et al. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer. ONCOLOGY LETTERS. 2020;20.\u003c/li\u003e\n \u003cli\u003eNaruse T, Yanamoto S, Okuyama K, Ohmori K, Tsuchihashi H, Furukawa K, et al. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. PATHOLOGY \u0026amp; ONCOLOGY RESEARCH. 2020;26:735-42.\u003c/li\u003e\n \u003cli\u003eShirasu H, Yokota T, Kawakami T, Hamauchi S, Onozawa Y, Ogawa H, et al. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2020;25:1914-20.\u003c/li\u003e\n \u003cli\u003eWang J, Jia J, Zhou L. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis. NEOPLASMA. 2020;67:1279-92.\u003c/li\u003e\n \u003cli\u003eWen JQ, Xu HY, Liu RY, Chen QX, Dai YH, Xu Y. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients. CELLULAR AND MOLECULAR BIOLOGY. 2020;66:24-31.\u003c/li\u003e\n \u003cli\u003eYang YQ, Sun X, Yan JH, Li Q, Ni Y, Ma HQ. The effect of neo-adjuvant chemotherapy on the improvement of oral cancer patients and the predictive value of miR-182 on its efficacy. JOURNAL OF BUON. 2020;25:2017-22.\u003c/li\u003e\n \u003cli\u003ePosner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med. 2006;354:634-6.\u003c/li\u003e\n \u003cli\u003eShen J, Shen H, Ke L, Chen J, Dang X, Liu B, et al. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol. 2022;13:815575.\u003c/li\u003e\n \u003cli\u003ePaccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265-72.\u003c/li\u003e\n \u003cli\u003eLicitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21:327-33.\u003c/li\u003e\n \u003cli\u003eCohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735-43.\u003c/li\u003e\n \u003cli\u003ePignon J-P, le Ma\u0026icirc;tre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92.\u003c/li\u003e\n \u003cli\u003ePignon JP, Bourhis J, Domenge C, Design\u0026eacute; L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-55.\u003c/li\u003e\n \u003cli\u003eKirita T, Ohgi K, Shimooka H, Yamanaka Y, Tatebayashi S, Yamamoto K, et al. Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results. Oral Oncol. 1999;35:597-606.\u003c/li\u003e\n \u003cli\u003eKirita T, Yamanaka Y, Imai Y, Yamakawa N, Aoki K, Nakagawa Y, et al. Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg. 2012;41:421-8.\u003c/li\u003e\n \u003cli\u003eKlug C, Berzaczy D, Voracek M, Millesi W. Preoperative chemoradiotherapy in the management of oral cancer: a review. J Craniomaxillofac Surg. 2008;36:75-88.\u003c/li\u003e\n \u003cli\u003eKlug C, Berzaczy D, Voracek M, Nell C, Ploder O, Millesi W, et al. Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients. J Craniomaxillofac Surg. 2009;37:344-7.\u003c/li\u003e\n \u003cli\u003eEich HT, L\u0026ouml;schcke M, Scheer M, Kocher M, Bongartz R, Wacker S, et al. Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity. Outcome of 134 patients. Strahlenther Onkol. 2008;184:23-9.\u003c/li\u003e\n \u003cli\u003eMeng X, Lou Q-Y, Yang W-Y, Wang Y-R, Chen R, Wang L, et al. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond). 2021;41.\u003c/li\u003e\n \u003cli\u003eBudach V. TPF sequential therapy: when and for whom? Oncologist. 2010;15 Suppl 3:13-8.\u003c/li\u003e\n \u003cli\u003eSpecenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol. 2017;28:2219-24.\u003c/li\u003e\n \u003cli\u003eHaddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, et al. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019;30:471-7.\u003c/li\u003e\n \u003cli\u003eHarada K, Ferdous T, Kobayashi H, Ueyama Y. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-\u0026kappa;B activity in human oral squamous cell carcinoma cell lines. Int J Oncol. 2014;45:2439-45.\u003c/li\u003e\n \u003cli\u003eSawatani Y, Komiyama Y, Nakashiro K-I, Uchida D, Fukumoto C, Shimura M, et al. Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro. Int J Mol Sci. 2020;21.\u003c/li\u003e\n \u003cli\u003eZhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40.\u003c/li\u003e\n \u003cli\u003eChen T, Ning J, Campisi A, Dell\u0026apos;Amore A, Ciarrocchi AP, Li Z, et al. Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC: A Retrospective Study. Ann Thorac Surg. 2022;113:993-9.\u003c/li\u003e\n \u003cli\u003eHao W, Zhang J, Wang Y, Fang B, Jin S, Yuan J, et al. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis. Front Immunol. 2023;14:1175809.\u003c/li\u003e\n \u003cli\u003eLorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12:153-9.\u003c/li\u003e\n \u003cli\u003eMehanna H, Rischin D, Wong SJ, Gregoire V, Ferris R, Waldron J, et al. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. J Clin Oncol. 2020;38:2552-7.\u003c/li\u003e\n \u003cli\u003eRobbins KT, Kumar P, Regine WF, Wong FS, Weir AB, Flick P, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38:263-71.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Oral squamous cell carcinoma, induction chemotherapy, bibliometric study, VOSviewer, CiteSpace","lastPublishedDoi":"10.21203/rs.3.rs-4705733/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4705733/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjectives: \u003c/strong\u003eOral squamous cell carcinoma (OSCC) is a prevalent malignant tumor worldwide, posing a significant threat to patient survival. Induction chemotherapy (IC) is an established therapeutic approach for advanced, unresectable OSCC, proven effective in controlling tumor progression and preventing distant metastasis. Despite its clinical significance, there is a lack of bibliometric studies in this research domain. This article aims to address this gap by conducting a comprehensive bibliometric analysis, which will shed light on the key areas of focus and provide insights into the research landscape of OSCC induction chemotherapy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eThe relevant articles were identified using the Web of Science Core Collection (WoSCC). To examine the co-occurrence relationships across countries/regions, institutes, authors (cited authors), journals (cited journals), references, and keywords in this research field, bibliometric analysis was conducted with the assistance of two software tools, VOSviewer and CiteSpace. This approach enables a comprehensive exploration of the frontiers and hotspots within the field.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eA comprehensive collection of 227 publications was assembled between 2000 and 2022. Overall, both the number of publications and citations display a steady annual increase, with the peak observed in 2021 and 2022. China and the United States jointly occupy the first rank in terms of total publications (n = 46), with Japan following closely behind (n = 32). Among the academic institutions, Shanghai Jiao Tong University has made the most substantial contribution, with 26 publications. In the realm of authors, Zhong Laiping secures the top position in the list of the top 10 authors (n = 13), whereas Posner MR and Vermorken JB are equally distinguished as the most co-cited authors (n = 104). The research field's most prolific journal is Oral Oncology, which boasts the highest number of publications (n = 24), while the Journal of Clinical Oncology claims the greatest number of co-citations. Conducting a co-occurrence and cluster analysis on the references cited, it was discovered that the recent research focus has shifted from radiochemotherapy and oral cancer to paclitaxel. Keyword analysis unveils that current research on induction chemotherapy for OSCC underscores the significance of chemotherapeutic drugs such as cisplatin, docetaxel, and fluorouracil.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion: \u003c/strong\u003eDespite the relatively modest number of publications, research on induction chemotherapy for OSCC is steadily growing. Currently, the primary focus of investigation revolves around drug selection for this therapeutic approach. This article provides an overview of the prevailing trends in this field and identifies potential directions and hotspots for future research.\u003c/p\u003e","manuscriptTitle":"Frontiers and hotspots in induction chemotherapy of oral squamous cell carcinoma: a bibliometric and visualized study from 2000 to 2022 by Bioinformatics and Cancer Database Analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-13 03:04:55","doi":"10.21203/rs.3.rs-4705733/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"0e05b8f6-aa8f-4121-8ac9-46f53a2ff389","owner":[],"postedDate":"August 13th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-09-06T10:42:34+00:00","versionOfRecord":[],"versionCreatedAt":"2024-08-13 03:04:55","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4705733","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4705733","identity":"rs-4705733","version":["v1"]},"buildId":"cBFmMYwuxLRRLfASyISRj","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}